Winbro Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.80 M
- Company Age 21 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 0.56 M
- Revenue Growth -99.63%
- Profit Growth -368.46%
- Ebitda -762.25%
- Net Worth -140.67%
- Total Assets 20.52%
About Winbro Pharma
Winbro Pharma Private Limited (WPPL) is a Private Limited Indian Non-Government Company incorporated in India on 05 December 2003 and has a history of 21 years and two months. Its registered office is in Chennai, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.80 M.
The company currently has active open charges totaling ₹0.56 M.
Renganathan Reddiar and Malarselvi Renganathan serve as directors at the Company.
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24231TN2003PTC052087
- Company No.
052087
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Dec 2003
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Winbro Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Renganathan Reddiar  | Director | 05-Dec-2003 | Current |
| Malarselvi Renganathan | Director | 02-Nov-2020 | Current |
Financial Performance of Winbro Pharma.
Winbro Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 99.63% decrease. The company also saw a substantial fall in profitability, with a 368.46% decrease in profit. The company's net worth observed a substantial decline by a decrease of 140.67%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Winbro Pharma?
In 2023, Winbro Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Windia Chemicals Private LimitedRenganathan Reddiar and Malarselvi Renganathan are mutual person
Windia Shrimp Farm Private LimitedRenganathan Reddiar and Malarselvi Renganathan are mutual person
Charges (Loans)
₹0.56 M
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 0.06 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 12 Apr 2022 | Hdfc Bank Limited | ₹0.56 M | Open |
How Many Employees Work at Winbro Pharma?
Unlock and access historical data on people associated with Winbro Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Winbro Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Winbro Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
